Strome’s Insider Buy Spurs Investor Interest in Zivo Bioscience’s Algae‑Derived Innovation
Strome’s 12.6% stake in Zivo Bioscience fuels new optimism around its algae‑derived ingredients, with insider buying, ESG appeal and rising social‑media buzz signaling potential upside.
4 minutes to read









